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Abstract
Background: With the advent of whole-genome analysis for profiling tumor tissue, a pressing need has emerged
for principled methods of organizing the large amounts of resulting genomic information. We propose the
concept of multiplicity measures on cancer and gene networks to organize the information in a clinically
meaningful manner. Multiplicity applied in this context extends Fearon and Vogelstein’s multi-hit genetic model of
colorectal carcinoma across multiple cancers.
Methods: Using the Catalogue of Somatic Mutations in Cancer (COSMIC), we construct networks of interacting
cancers and genes. Multiplicity is calculated by evaluating the number of cancers and genes linked by the
measurement of a somatic mutation. The Kamada-Kawai algorithm is used to find a two-dimensional minimum
energy solution with multiplicity as an input similarity measure. Cancers and genes are positioned in two
dimensions according to this similarity. A third dimension is added to the network by assigning a maximal
multiplicity to each cancer or gene. Hierarchical clustering within this three-dimensional network is used to identify
similar clusters in somatic mutation patterns across cancer types.
Results: The clustering of genes in a three-dimensional network reveals a similarity in acquired mutations across
different cancer types. Surprisingly, the clusters separate known causal mutations. The multiplicity clustering
technique identifies a set of causal genes with an area under the ROC curve of 0.84 versus 0.57 when clustering on
gene mutation rate alone. The cluster multiplicity value and number of causal genes are positively correlated via
Spearman’s Rank Order correlation (rs(8) = 0.894, Spearman’s t = 17.48, p < 0.05). A clustering analysis of cancer
types segregates different types of cancer. All blood tumors cluster together, and the cluster multiplicity values
differ significantly (Kruskal-Wallis, H = 16.98, df =2 ,p < 0.05).
Conclusion: We demonstrate the principle of multiplicity for organizing somatic mutations and cancers in clinically
relevant clusters. These clusters of cancers and mutations provide representations that identify segregations of
cancer and genes driving cancer progression.
Background
Under the inundation of data from whole-genome ana-
lysis of tumors [1], researchers wonder if the aftermath
will be a hopelessly complex cancer landscape [2]. For
instance, a 2007 study examined somatic mutations
across the genome for colorectal carcinoma, one of the
most common cancers occurring in epithelial tissue, and
observed that a median of 76 non-silent mutations (15
considered to be in candidate cancer genes) had
occurred in each tumor [2]. The same study identified a
mean of 101 non-silent mutations in a set of breast car-
cinomas, another common epithelial cancer. As the use
of whole-genome sequence analysis increases, the need
to organize information about tumor somatic mutation
patterns becomes more urgent.
Extant methods [3] to handle the influx of data focus
on aggregating data into pathways rather than single-
gene focused approaches. The logic of a pathway
approach is tied to the observation that gene mutations
tend to be exclusive within a pathway [4,5]. The diffi-
culty is that pathways are complex and not mutually
exclusive, so defining which pathway a mutation impacts
can be open to interpretation; for example, KRAS is a
member of 34 pathways and PIK3CA belongs in 37 [6].
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pathways, a method is needed to group genes into
mutually exclusive sets that are biologically or clinically
relevant. This method reduces the complexity of non-
exclusivity that occurs with pathway analysis. The pur-
pose of exclusive sets of genes with somatic mutations
is to separate the “wheat from the chaff” or identify
which genes are gatekeepers, drivers, or passengers [7,8].
Fearon and Vogelstein introduced a multi-hit genetic
model of tumor progression for colorectal cancer patho-
genesis based on an accumulation of multiple somatic
mutations [9]. This landmark model illustrated that as
mutations occur in key genes, normal cells are trans-
formed into communities that proliferate in excess,
without adequate apoptosis, and eventually become
malignant. The process can be mapped onto histologi-
cally recognizable states as colonic tissue progresses
from normal mucosa to adenoma (polyp), adenoma with
high-grade dysplasia (a more aggressive polyp closer to
an invasive state), and finally invasion. Fearon and
Vogelstein observed that these mutations typically occur
in a recurring sequence, yet the order of the mutations
is less important than their cumulative effect.
Our approach extends the concept of multiple hits
across cancer types to demonstrate how this type of
knowledge representation can be generalized beyond col-
orectal cancer. Building on Fearon and Vogelstein’s multi-
hit genetic model of colorectal tumor progression [9], this
paper examines the concept of multiplicity of genes with
somatic mutations across cancers as an organizing princi-
ple for analysis of previous and future somatic mutation
data. Multiplicity is measured by counting the number of
cancers shared by pairs of genes. This gives a measure of
similarity between genes based on the number of overlap-
ping cancers between genes. These similarity distances
between genes can be used to generate mutually exclusive
clusters of genes. The utility of the clusters can be assessed
using prior knowledge of cancers and genes.
Multiplicity has been used in social network analysis
to identify key actors driving events in capital markets
[10]. The social network analysis tool Pajek [10] displays
actors’ relationships in a three-dimensional landscape,
allowing the detection of patterns not visible on a two-
dimensional surface. By treating genes and cancers as
actors and events using social network analysis techni-
ques, we found evidence of patterns in cancer and gene
multiplicity landscapes.
The following sections discuss two experiments that
examine the concept of multiplicity. The first study tests
whether high multiplicity scores correlate with known
causal genes; it also explores the use of multiplicity
combined with hierarchical clustering to organize
mutated genes. The second study examines the utility of
multiplicity in clustering cancer types.
Methods
Experiment 1 examines the utility of multiplicity and
clustering methods for mutated genes. A clustering hier-
archy is generated with mutated genes as the focus. We
then compared the generated clusters to the Wellcome
Trust Sanger Institute’s list of known germline muta-
tions [11] to test for associations related to multiplicity
and known causal mutations.
Data
Over past decades, hundreds of thousands of tumor
samples have been examined for somatic mutations and
reported in the literature. Consequently, thousands of
somatic mutations have been linked to hundreds of dif-
ferent cancer types [12]. Researchers at the Wellcome
Trust Sanger Institute have manually curated somatic
mutation information available through research publi-
cations into a public database called the Catalogue of
Somatic Mutations in Cancer (COSMIC) [13,14]. We
use hierarchical clustering of somatic mutation profiles
randomly sampled from the COSMIC resource to iden-
tify high multiplicity similarities in somatic mutation
patterns across cancer types.
For our analysis, we use the July 2010 COSMIC (v48)
containing data for 18,490 genes, 136,326 mutant tissue
samples, and 2,720,220 experiments. In those samples,
141,212 unique mutations are identified. These data are
extracted from 10,383 articles published between 1984
and 2010. The curators for the COSMIC database point
out that the classification of tumor types in the pub-
lished literature is variable both in terms of the level of
granularity provided in a single publication and in terms
of the prevailing classification system used for a particu-
lar cancer type. To standardize the tissue and histology
information stored in their database, COSMIC curators
developed a tumor classification scheme using generally
understood terminology. They translate tissue and his-
tology information into the COSMIC classification
scheme before entering it into the database. A mapping
of published terminologies and the COSMIC classifica-
tion scheme is available from the Sanger website [14].
We first defined cancer type as a combination of COS-
MIC information that informed us of the tumor’sa n a -
t o m i cs i t eo rt i s s u et y p eo fo r i g i na n dt h et u m o r ’s
histology. We selected the most granular histological
classifier for which we were able to maintain sufficient
sample size to provide power for the analysis while ade-
quately classifying the disease for biological
interpretation.
We selected the “Site_Primary_COSMIC” value for all
anatomic site or tissue types represented. In general,
COSMIC contained data on too few samples with desig-
nated subtypes for tumors of epithelial origin to classify
them beyond histology of adenoma or carcinoma.
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nated the COSMIC anatomic site of a tumor (called
“Site_Primary_COSMIC”) with the highest-level histolo-
gical classifier (called “Histology_COSMIC”)t od e f i n e
cancer types. We used a similar concatenation for soft
tissue tumors, categorizing the tumor types using the
highest level histology available (e.g., gastrointestinal
stromal tumors).
In contrast, we found that the highest level histologi-
cal classifier separated tumors of the “hematopoietic and
lymphoid” tissue type into two large groups, either
“hematopoietic neoplasm” or “lymphoid neoplasm.” In
these cases, we used the histological subtype (e.g.,
“chronic myeloid leukemia”) to classify the tumor type
b e c a u s ei tm o r ea c c u r a t e l yr e p r e s e n t st h et u m o rt y p e ,
and there are sufficient samples to make the analysis
meaningful. Similarly, with central nervous system
tumors, we were able to group the gliomas into subtypes
(e.g., astrocytoma grade IV).
Gene substitutions, insertions, and deletions are classi-
fied uniformly as mutations. In some genes (e.g., JAK2,
KRAS, PDGFRA), mutations are focused mainly within a
few key sequence regions; in others (e.g., APC, TP53,
CDKN2A), infrequent mutations are spread across hun-
dreds of positions within the gene. To maintain compu-
tational feasibility and in an attempt to represent
higher-level biological effects, we aggregate mutations at
the gene level rather than considering each mutation as
a distinct feature.
In preliminary work, we found that differences in the
sample sizes for cancer types resulted in the larger sam-
ples having more weight in the clustering. This, along
with the selection bias for the measured genes, makes
normalization through clustering difficult. For this inves-
tigation, we forced equal sample sizes (N = 4000) by
restricting our investigation to cancer types with 4,000
or more samples in COSMIC, randomly sampling 4,000
mutant tissue samples per cancer type from COSMIC.
The analysis uses the closed-world assumption of data-
bases [15], where a mutation exists if and only if there
is positive evidence for the mutation.
Known causal genes
COSMIC also includes a listing of known causal germ-
line gene mutations. We obtained the counts for the
known causal gene mutations by intersecting Sanger
Institute’s 75 known germline mutation genes [11] with
the 489 genes included in the network. This results in
an intersecting set of 34 genes. We acknowledge many
other causal genes identified in the literature, but our
analysis focuses on Sanger Institute’sr e c o g n i z e dc a u s a l
germline mutations. Additionally, these germline muta-
tions have been identified through genetic linkage stu-
dies of cancer pedigrees [16] and are used as a means of
early detection and treatment of cancers through
screening.
Hierarchical clustering technique
We used the Ward hierarchical clustering technique
[17] as implemented in Pajek [10] to cluster data using
the Euclidean distance between genes. The generation of
the clusters involves several steps: construct two-mode
cancer and gene network, produce one-mode gene net-
work and one-mode cancer network, calculate gene
multiplicity values, generate Kamada-Kawai two-dimen-
sional plane, compute 3D similarity matrix, and find
hierarchical clusters.
Two-mode network for cancers and genes
A network is constructed with nodes being cancers
types and genes, and links being the relationship
between cancers types and genes. This results in a two-
mode network with cancers being one of the modes and
genes being the other. Cancers within the two-mode
network are associated only with genes and genes are
associated only with cancers (Figure 1, left side). For the
two-mode network generated from COSMIC data, a
link between a mutated gene and a cancer type is
included in the network if the gene’s mutation rate for a
given cancer type is better than chance as tested by a
chi-square goodness-of-fit test (p < 0.05). This results in
29 types of cancer and 489 genes with mutations in the
network.
One-mode network for genes
The two-mode graph is converted to a one-mode graph
(Figure 1, top right side) of multiplicity-related genes in
which the multiplicity of the link represents the number
of cancers in which the linked genes have occurred
together. As illustrated in Figure 1, genes a and b share
links only through Cancer B,s ot h e i rlink multiplicity is
one.
Gene maximum multiplicity value
A multiplicity-slice (m-slice) [10] is then applied to the
graph, giving a multiplicity value to each gene in the
network derived from the maximal multiplicity of the
links within a gene’s set of directly connected genes. For
example in Figure 1, a gene maximum multiplicity value
of 2 is listed inside all the nodes since each node has a
maximum multiplicity link of magnitude 2.
Specifically, gene maximum multiplicity (Eq. 1, Gene-
MaxMultiplicity) and gene link multiplicity (Eq. 2, Gen-
eLinkMultiplicity) are defined as follows. Let G be the
set of genes, C be the set of cancers, and C’ij be the set
of cancers such that both genes i and j are mutated in
cancer k more than chance as measured by chi-squared
at alpha 0.05.
GeneMaxMultiplicityi =m a x j∈G
 
GeneLinkMultiplicityij
 
(1)
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⎫
⎪ ⎬
⎪ ⎭
(2)
Thus, gene maximum multiplicity is larger for genes
that occur systemically across cancers. Gene maximum
multiplicity serves as a measure of a gene’s systemic
occurrence and hence a gene’s potential to be a driver
mutation rather than a passenger mutation.
Kamada-Kawai two-dimensional plane
The gene network is then arranged in a two-dimensional
space using the Kamada-Kawai network drawing algo-
rithm [18] implemented in Pajek [10]. The algorithm
arranges the genes according to minimum energy of the
system with the links between genes being analogous to
springs [18]. In Figure 1, Genes c and d are more similar
to each other, with a gene link multiplicity value of 2,t h a n
Genes a and b, with a gene link multiplicity of 1. Conse-
quently, Genes c and d w o u l db ec l o s e rt oe a c ho t h e ri n
the two-dimensional space solved for minimum energy.
Cancer A
Cancer C
Cancer B
Gene a
Gene b
Gene d
Gene c
Two-Mode Network (Cancers & Genes)
One-Mode Network (Genes)
Gene a Gene b
Gene d Gene c
22
2
1
2 2
2
2
2
2
Cancer A
Cancer C Cancer B
2 1
3 3 3
2
One-Mode Network (Cancers)
Figure 1 Examples of two-mode and one-mode networks. The example two-mode network on the left side has links only between cancers
and genes. On the right side, one-mode networks of genes (upper) or cancers (lower) are derived from the two-mode network. The number on
each link corresponds to the number of shared cancers between the genes in the upper network and the number of shared genes between the
cancers in the lower. The number within each node is the maximal value for the links connected to the node.
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as a third-dimension perpendicular to the Kamada-
Kawai two-dimensional plane. Thus, each gene has an
associated x, y and z coordinate based on its position in
the Kamada-Kawai plane and its gene maximum multi-
plicity value.
Three-dimensional similarity matrix and hierarchical
clustering
We computed a similarity matrix by calculating the
Euclidean distance between the three-dimensional coor-
dinates for each gene in the network. We then used the
similarity matrix to construct the hierarchical clustering
given the distances between the genes. This Euclidean
distance clustering approach overcomes the cluster
instability limitation due to sparse data reported with
previous methods applied to COSMIC [19].
Network method for Experiment 2
Experiment 2 applies the same methods as Experiment
1, but focuses on cancer types rather than mutated
genes. The approach constructs a network of cancer
types with a cancer maximum multiplicity measure
establishing the similarity and dissimilarity between can-
cer types. Given cancer maximum multiplicity derived
distances, a hierarchical clustering technique is used to
generate meaningful clusters. Experiment 2 uses the
same data sets as Experiment 1. The data sets and selec-
tion process are described in Experiment 1.
Experiment 2 uses the same graph methodology as
Experiment 1, performed for cancer types rather than
mutated genes. The one-mode graph links cancers in
which the multiplicity of the links between the cancer
types represents the number of genes they share. Similar
to Experiment 1 for gene maximum multiplicity, the
cancer maximum multiplicity value for a cancer type is
obtained from its maximum value link to any cancer
type in the graph. Specifically, cancer maximum multi-
plicity (Eq. 3, CancerMaxMultiplicity) and cancer link
multiplicity (Eq. 4, CancerLinkMultiplicity) are defined
as follows:
CancerMaxMultiplicityi =m a x j∈C
 
CancerLinkMultiplicityij
 
(3)
CancerLinkMultiplicityij =
  
k∈G wijk
 
 
wijk =1
wijk =0
 
   i,j ∈ C,k ∈ G 
ij ⊆ G
 
 i  = j
 
   i,j ∈ C,k ∈ G − G 
ij
⎫
⎪ ⎬
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(4)
Results
For Experiment 1, we have generated five results for
mutated genes using the above network representation:
(1) a two-sample Kolmogorov-Smirnov test to show
whether higher gene maximum multiplicity values occur
with known causal genes, (2) a paired histogram com-
paring average gene maximum multiplicity of clusters
with counts of known causal genes within clusters, (3) a
dendrogram of gene clusters generated by hierarchical
clustering, (4) a clustering of germline mutations only,
and (5) a comparison of the different measures for clus-
tering the somatic mutation data.
Gene maximum multiplicity and causal genes
The observed gene maximum multiplicity values for
each gene ranged from 1 to 23. Overall, genes with high
gene maximum multiplicity scores were significantly
more likely to be causal genes than those with lower
gene maximum multiplicity scores (two-sample Kolmo-
gorov-Smirnov test, one-tail, D34, 455 = 0.632, p <0 . 0 5 ) .
The median gene maximum multiplicity score for
known causal genes was 5.5; for all other genes, it was
1.0.
Gene clusters
The Ward hierarchical clustering technique [10,17]
resulted in ten clusters (see Experiment 1 description of
technique). The dissimilarity threshold of 5.07 was cho-
sen from inspection of the dendrogram for a cluster cut
point. The clusters are depicted in Figure 2. Cluster 4
has the highest average multiplicity of 10.3. The lower
portion of Figure 2 provides a detailed view of cluster 4.
Note that this cluster contains 18 known causal gene
mutations (see asterisks in Figure 2, cluster 4).
Average gene maximum multiplicity for clusters and
causal genes
Figure 3 displays the histogram showing the average
gene maximum multiplicity value for the ten clusters
derived from the hierarchical clustering method
depicted in Figure 2. The average gene maximum multi-
plicity for a cluster is obtained by averaging the gene
maximum multiplicity values of the individual genes
within a cluster. The observed gene maximum multipli-
city values for each cluster range from 1.0 to 10.3 (see
Figure 3). We tallied the causal genes for each mutually
exclusive cluster to generate the histogram of causal
gene counts per cluster. The number of causal genes
observed in each cluster ranges from 0 to 18 and is pre-
sented in Figure 3.
A disproportionate allocation of causal gene mutations
occurs within clusters having a high average gene maxi-
mum multiplicity value. Clusters 1, 2, 3 and 4 all have
average gene maximum multiplicity values greater than
2.0, and they have a disproportionate number of known
causal gene mutations (31 of 34). Cluster 4, with 18 cau-
sal mutations, is the highest-ranking cluster, with an
Frey et al. BMC Medical Genomics 2011, 4:52
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contains more than half the intersecting casual muta-
tions. There is a strong positive correlation between
average gene maximum multiplicity values for clusters
and number of causal genes per cluster (rs(8) = 0.894,
Spearman’s t = 17.48, p < 0.05).
Three-dimensional gene representation
Figure 4 displays the three-dimensional layout with
colors representing each cluster. Cluster 4 (black
symbols) projects on a central axis perpendicular to
the two-dimensional plane of the Kamada-Kawai lay-
out. This cluster contains the greatest number of
Figure 2 Graphical depiction of the gene clustering. The clustering of the 489 genes derived from their Euclidean distances in the Kamada-
Kawai and gene maximum multiplicity three-dimensional space. The dissimilarity distance calculated in the Ward hierarchy ranges from 0.0 to
41.09. The dissimilarity threshold for the clusters is 5.07. The lower portion of the figure depicts cluster 4, which has the highest gene maximum
multiplicity value of 10.3. The asterisks mark the known causal gene mutations within this cluster.
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Figure 3 Histogram for the average gene maximum multiplicity value for the clusters. The histogram depicts the average gene maximum
multiplicity values for the ten clusters derived from the hierarchical clustering method presented in Figure 2. The average gene maximum
multiplicity for a cluster is obtained by averaging the gene maximum multiplicity values of the genes within a cluster. The causal genes are
tallied for each mutually exclusive cluster to generate the histogram of causal gene counts per cluster.
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Page 6 of 15known causal genes and has the highest multiplicity
values.
The three-dimensional representation reveals addi-
tional information beyond the driver genes alone. For
example, clusters 8, 9 and 10 are all associated with
astrocytoma grade IV, and the genes have clustered
together tightly. Cluster 5 primarily has genes associated
with ovarian cancer, cluster 6 has a large proportion of
genes associated with breast and lung cancers, and clus-
ter 7 has a large proportion of genes associated with
breast and central nervous system cancers. Cluster 3 has
systemic genes that occur across many of the cancers
and a concentration of genes associated with the blood
cancers. Clusters 1 and 2 have genes that are primarily
associated with carcinomas. Cluster 4 has systemic
genes that occur across many of the 29 cancers. Cluster
4 also contains all but 1 of the 24 genes associated with
the precancerous tumors: large intestine adenoma, thyr-
oid adenoma, and gastrointestinal stromal tumor. The
simpler one-dimensional measure, gene maximum mul-
tiplicity alone, provides none of this information.
Clustering of germline mutations only
Clustering only on the 34 causal germline mutations
results in pattern similar to Figure 4 but with fewer
genes. Additional File 1 presents a graphical representa-
tion of the hierarchical clustering for these 34 causal
germline mutations.
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Figure 4 Three-dimensional gene maximum multiplicity representation. The three-dimensional representation of cancer is derived from the
combination of the x and y dimensions of the Kamada-Kawai network with a z-dimension for the gene maximum multiplicity values. Each color
denotes one of the ten clusters. The clusters are derived from the Euclidean distances between nodes in the Kamada-Kawai network layout with
a perpendicular gene multiplicity dimension. The color-coded numeric label for each cluster is listed near the points for that cluster.
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We compared four different measures for clustering the
somatic mutation data: (1) clustering on the three-
dimensional combination of the Kamada and Kawai and
gene maximum multiplicity, (2) clustering on the one-
dimensional representation of gene maximum multipli-
city, (3) clustering on the two-dimensional Kamada and
Kawai representation, and (4) clustering on the one-
dimensional representation of the genes’ mutation rates.
We calculated thresholds for predicting germline genes
by the cluster’s average gene maximum multiplicity
value divided by the maximum of these average values
over the clusters. The same method is applied for muta-
tion rate, with average mutation rate for a cluster being
substituted for average gene maximum multiplicity rate.
The results for the four comparisons are 10, 3, 9, and 5
clusters, respectively. The number of clusters for each
comparison was determined by the distance between
clusters in each dendrogram. As shown in Table 1,
three-dimensional clustering performs the best overall,
with 0.84 area under the receiver operating characteris-
tic (ROC) curve. This is only a 0.01 improvement over
the one-dimensional gene maximum multiplicity cluster-
ing, so gene maximum multiplicity is the primary mea-
sure generating the clusters that differentiate germline
mutations from non-germline mutations. Contrast this
with mutation rate, 0.57 area under the ROC, account-
ing for 21 of the 34 germline mutations in the top 489
genes. Mutation rate results in a maximum sensitivity of
only 62% of the genes for the germline comparison. The
clustering on two dimensions performs poorly compared
to the three-dimensional and one-dimensional cluster-
ings. It creates a large cluster in the center in the
Kamada-Kawai, which does not distinguish well between
germline mutations and non-germline mutations.
The result listed in Table 1 supports using the simpler
one-dimensional measure of gene maximum multiplicity
to predict germline mutations. However, although the
gain in area under the ROC is slight, the three-
dimensional graph representation provides valuable spa-
tial information. Additional File 2 provides a gene maxi-
mum multiplicity value for each gene.
In the COSMIC data set, there is a confounding influ-
ence of bias in which commonly measured genes tend
to be those known to be associated with cancer progres-
sion. Clinicians and researchers use prior knowledge to
select genes for measurement that they think are most
relevant to the particular cancer. Consequently, one
could argue that gene maximum multiplicity merely
capitalizes on a bias in the data set. To address this con-
cern, we examined the correlation between the number
of measurements on specific genes and the gene maxi-
mum multiplicity measure on those genes. A significant
positive correlation was found between gene maximum
multiplicity and the frequency of gene measurement (rp
(487) = 0.74, Pearson’s t =2 3 . 9 ,p <0 . 0 5 ) .W i t ha nR
2
of 54.8%, this suggests that about 55% of the variance
m i g h tb ee x p l a i n e dv i at h ef r e q u e n c yo fg e n em e a s u r e -
ment. The multiplicity measure not only successfully
identifies genes already known to be important; it also
gives high ranking to less frequently measured relevant
genes (see Table 2).
This suggests that prior knowledge selection bias
misses genes systemically mutating across cancers that
the gene maximum multiplicity measure can identify.
Although the COSMIC data set has limitations, the
gene maximum multiplicity measure can be used to find
candidate genes for investigation as systemic somatic
mutations. The measurement bias exhibited in COSMIC
can be further examined when whole genome sequence
data repositories for cancer [20] become sufficiently
populated to apply the gene maximum multiplicity
measure.
Biological implications of the gene clusters
The highest gene maximum multiplicity cluster, cluster
4, has a number of known genes associated with the
Table 1 Comparison of area under ROC for measures
Measures Dimension Area under
ROC
Kamada-Kawai and gene maximum
multiplicity
3D 0.84
Gene maximum multiplicity 1D 0.83
Kamada-Kawai 2D 0.79
Mutation rate 1D 0.57
Comparison of four different measures for clustering the somatic mutation
data: (1) a clustering which combines the two-dimensional representation of
the Kamada and Kawai and gene maximum multiplicity, (2) a clustering on
the one-dimensional representation of gene maximum multiplicity, (3) a
cluster on only the two-dimensional Kamada and Kawai representation, and
(4) a clustering on the one-dimensional representation of mutation rates of
the genes
Table 2 Large multiplicity values for genes that have a
low frequency of measurement
Gene Gene maximum
multiplicity value
Number of times measured in
analyzed data set
CDKN2a
(p14)
14 782
TTN 9 462
SMARCA4 7 1307
CSMD3 5 983
TAFIL 5 783
MTOR 4 941
Although there is a high correlation, a number of genes have above-average
gene maximum multiplicity values (average = 2.3) despite having a below-
average number of measurements (average = 1813.7). This table shows the
subset of genes with these characteristics.
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Page 8 of 15development of multiple types of cancer. For example, it
includes KRAS, APC, SMAD4 and TP53, genes from the
Vogelstein model of colorectal cancer progression
[9,16,21]; RB1 and NF1, well-known tumor suppressor
genes [3]; MET and PDGFRA, which are not listed in
the Sanger Institute file for germline mutations, but are
known to be causal for hereditary papillary renal cell
carcinoma and familial gastrointestinal stromal tumors,
respectively [3]; BRCA1 and BRCA2, both known to be
causal in the development of breast and ovarian cancer
[22,23]; and EGFR and ERBB2, both members of the
epidermal growth factor receptor family and known to
have roles in promoting proliferation and aggressive
behavior. In addition to depicting known causal genes,
the method implicates by association many other genes
that that occur across multiple cancers, suggesting their
possible significant role in cancer progression. These
implicated genes include TTN, BRAF, ATM, and TAF1L,
the top four protein kinase genes ranked by Greenman
and colleagues [8] as carrying at least one driver muta-
tion. This finding supports the logic of using gene maxi-
mum multiplicity as a key feature in our analysis. In
addition to organizing the data, this method allows us
to hypothesize that the other genes in cluster 4 have a
high probability of a causal role in progression.
Clusters 1, 2, and 3 are at cluster 4’s base and contain
a total of 13 known causal genes. These three clusters
have the next highest gene maximum multiplicity values.
The remaining clusters form a circular pattern at the
periphery and contain a total of 3 known causal genes.
Genes with higher gene maximum multiplicity values
will cluster more tightly on the central axis. This is evi-
dent with TP53, KRAS and CDKN2A, which have the
highest gene maximum multiplicity values and appear at
the tip of the central axis. The central axis can be
thought of as a common set of generally applicable gene
mechanisms for driving carcinogenesis in any cell type.
The higher the gene maximum multiplicity value, the
more broadly the gene occurs across the 29 cancers in
the network. At the base, genes that occur in subsets of
cancer types begin to fan out from the axis. Here we
begin to see genes specific to a certain cancer type or
anatomic location. We note that our data are biased
toward cancer types that include fully invasive or malig-
nant tumors, especially carcinomas. Therefore, the genes
that fan out from the axis tend to be associated with the
invasive state.
Three-dimensional cancer representation
For Experiment 2, we generated the following three
representations for cancer types: (1) three-dimensional
space of cancer types from which the clusters are
derived based on Euclidean distance; (2) a dendrogram
of specific cancer types within the clusters generated
using hierarchical clustering; and (3) a dendrogram
resulting from normalizing the cancer link multiplicity
by the mutation rate for the cancers connected by the
link.
Figure 5 displays the three-dimensional space derived
from the Kamada-Kawai two-dimensional graph layout,
with the cancer maximum multiplicity representing the
third dimension. The cancer maximum multiplicity
values of the cancers range from 4 to 53. The coordi-
nates are normalized to be within a unit space. The
minimum energy solution for the network results in
cancers with many links to other cancers being centrally
located in the two-dimensional space. The hematopoie-
tic and lymphoid tissue tumors share similar mutations
and group together in the three-dimensional space (See
Figure 5, red symbols and labels).
Most tumors in COSMIC, with over 4000 samples, are
fully invasive carcinomas. Thus, our analysis contains a
relatively small number of tumors that are either precur-
sors to an invasive state or are not frankly malignant (e.
g., adenomas, in situ carcinomas, and tumors with
unknown malignant potential). Of the data used, the
precancerous or not frankly malignant tumors and ade-
nomas (n = 3) tend to have lower cancer maximum
multiplicity values and appear in the same cluster (see
Figure 5, green symbols). The average cancer maximum
multiplicity values for clusters 1, 2, and 3 are 14.5, 8.11,
and 26.5, respectively. The ranks of the average of the
cancer maximum multiplicity values for clusters are sig-
nificantly different via a Kruskal-Wallis test (H = 16.98,
df =2 ,p < 0.05). Median multiplicity value for clusters
1, 2, and 3 are 15, 10, and 45, respectively.
We used the Ward hierarchical clustering technique
[10,17] to cluster the data using the Euclidean distance
between cancer types. Figure 6 focuses on the three
high-level clusters of cancer type. Hematopoietic cancers
cluster together (see red symbols in Figure 5). Lung can-
cer, malignant melanoma, and central nervous system
astrocytoma grade IV, all aggressive cancers, cluster
tightly. These cancers have the highest cancer maximum
multiplicity values (see blue symbols in Figure 5). Breast,
ovarian, and kidney cancers are also included in the
high cancer maximum multiplicity cluster. The third
cluster has a mixture of precancerous adenomas and
tumors, along with carcinomas (see green symbols in
Figure 5).
By normalizing the link weight between cancers
based on the cancer’s mutation rate, we obtained a
clustering less influenced by the number of mutations
occurring within each cancer. For example, astrocy-
toma grade IV has 299 mutated genes associated with
it, while large intestine adenoma has 10 mutations.
The mutation rate of a cancer does give information
about the aggressiveness of the cancer due to genetic
Frey et al. BMC Medical Genomics 2011, 4:52
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Page 9 of 15instability. Astrocytoma grade IV is in a much worse
state than adenoma of the large intestine. To normal-
ize the link between adenoma of the large intestine
and astrocytoma, we set the weight that each one con-
tributes as proportional to the inverse of its overall
number of mutations, so adenoma of the large intes-
tine would be weight 1/10 and astrocytoma grade IV
would be 1/299.
⎧
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Equation 5 provides the formulation of the normalized
link weight with || i || being the number of mutated
genes associated with cancer i. Figure 7 shows the hier-
archical clusters that result from clustering with normal-
ized link weights.
Comparing Figure 6 to Figure 7, the overall structure
of the clustering hierarchy is similar to the non-normal-
ized clusters. Three main clusters with high mutation
rate cancers remain together. The blood cancers still
cluster together under the normalization, but two acute
blood cancers, more aggressive and therefore more
unstable with respect to a unique genetic identity, clus-
ter with two other cancers that have high mutation
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Figure 5 Three-dimensional cancer maximum multiplicity representation. The three-dimensional representation of cancer is derived from
the combination of the x and y dimensions of the Kamada-Kawai network with a z-dimension for the cancer maximum multiplicity values. The
colors represent the three clusters generated from the Euclidean distances between cancer types as described in the text. Cluster 2, depicted in
red, contains only hematopoietic and lymphoid tissue tumors. Specific cancers depicted in the green, red and blue clusters are listed in Figure 6
under clusters 1, 2 and 3, respectively.
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Page 10 of 15rates, lung cancer and ovarian carcinoma. In the non-
normalized clustering, these two acute blood cancers
clearly cluster only with related blood cancers because
lung and ovarian cancers have high mutation rates and
have a larger distance from the blood cancers due to
high mutation rates. Normalization may in fact diminish
the distance between cancers, blurring of the boundaries
between certain cancer types. It may be that clustering
cancers by multiplicity and Euclidean distance is more
informative without the normalization step.
Biological implications of cancer type clusters
The biological basis of the strong central cluster of
hematopoietic tumors (Cluster 2) is straightforward.
Clusters 1 and 3, which each contain several tumor
types, require a closer examination of their associations.
One subcluster in cluster 3 contains Grade IV astrocyto-
mas, malignant melanomas, and lung carcinomas. Astro-
cytomas and melanomas both originate from neural
crest tissue, as do the subset of lung carcinomas that are
either pure neuroendocrine carcinomas (such as small
cell carcinoma of the lung) or contain neuroendocrine
differentiation. It is also known that EGFR mutations or
amplifications play a role in lung adenocarcinomas
[24,25], uveal melanomas [26], and possibly in high-
grade gliomas [27], although the role EGFR plays with
respect to clinical behavior of the tumor has been con-
troversial [28].
In the first part of this paper, EGFR can be located on
a central axis of genetic mutations with the highest gene
maximum multiplicity (see Figure 2), and that therefore
may represent an axis of genetic instability that leads to
progression into and across neoplastic states from a pro-
liferating clone to a frankly malignant tumor. These
tumor types may cluster based on genetic instability,
possibly introduced or associated with EGFR amplifica-
tions. The relationship with neural differentiation is not
clear.
The second subcluster of cluster 3 includes breast,
ovarian, and kidney carcinomas. Relationships between
breast and ovarian carcinomas have been established,
including association with a germline mutation in
BRCA2 and the influence of reproductive steroid hor-
mone receptors. The association with kidney carcinomas
is novel in this analysis, but may be due to the fact that
a number of urothelial carcinomas express Erbb2 (also
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Figure 6 Graphical depiction of the cancer clustering. The clustering of the 29 cancer types derived from their Euclidean distances in the
Kamada-Kawai and cancer maximum multiplicity three-dimensional space. The dissimilarity distance calculated in the Ward hierarchy ranges
from 0.0 to 3.42.
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Page 11 of 15known as Her2neu [29]), which interacts with EGFR and
may introduce genetic instability leading to high cancer
maximum multiplicity in this analysis.
Cluster 1 is relatively heterogeneous, including adeno-
mas, at least one tumor of unknown malignant potential
(gastrointestinal stromal tumors), and carcinomas. The
mean cancer maximum multiplicity for cluster 1 is con-
siderably lower than cluster 3 (15 compared with 45),
and this cluster may not have biological meaning other
than a moderate degree of genetic instability. It is inter-
esting to note that the majority of the tumors are from
the gastrointestinal tract (esophageal, intestinal of any
type, stomach, pancreas, and liver).
Discussion
Despite its limitations, the COSMIC database is a valu-
able resource that brings together findings from thou-
sands of studies; our methods demonstrate the extraction
of meaningful knowledge representations from this
resource. With the onslaught of whole genome analysis
data quickly approaching, the need for methods of mean-
ingful knowledge representation grows ever more urgent.
We provide a robust method for organizing genome data,
derived from decades of cancer research on somatic
mutations, into a knowledge representation that is useful
for the bench researcher and clinician. Our research
demonstrates an organizing principle based on the multi-
plicity of somatic mutations that could potentially aid
researchers and physicians in the discovery of broad-
based causative gene mutations versus sporadic muta-
tions within specific tumor types.
The methodology identifies clusters of genes known to
drive proliferating cells toward carcinoma. Many of the
genes in the central axis (i.e., those with high gene max-
imum multiplicity values) have a direct relationship to
cell cycle regulation. This is consistent with the hypoth-
esis that genes appearing along the central axis are a set
of driver genes, given that imbalance between cell pro-
motion and cell death results in tumor progression [7].
By association, other genes in clusters with high gene
maximum multiplicity values are potentially driver
genes. In contrast, mutations in genes with lower gene
maximum multiplicity values may be associated with the
environment (anatomic location) and the specific cell
type in which they occur. Another measure of multipli-
city, signature multiplicity [30], is the phenomenon of
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Figure 7 Graphical depiction of the normalized cancer clustering. Using normalized link weights, the clustering of the 29 cancer types
derived from their Euclidean distances in the Kamada-Kawai and cancer maximum multiplicity three-dimensional space. The dissimilarity distance
calculated in the Ward hierarchy ranges from 0 to 2.85.
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Page 12 of 15multiple optimally predictive signatures of phenotype in
high throughput data. The concept of multiplicity intro-
duced in this paper focuses on measuring the systemic
occurrence of genes across multiple phenotypes to cre-
ate clusters. A more extensive comparison between the
two multiplicity approaches will be possible when suffi-
cient samples of next-generation sequence data are
available on multiple cancer types.
Our research shows that informatics can be used to
search data collected from previous studies to discover
novel relationships and patterns in the data. With the
use of high-throughput technologies that measure the
characteristics of well-annotated samples specifically
designed to characterize the cancers with multiplicity
measures, there is the potential for further confirmatory
and new discoveries.
Even given the limitations of the COSMIC data set,
there is support for the hypothesis that multiplicity mea-
sures can be used to distinguish early from late cancers.
The adenomas tend have lower cancer maximum multipli-
city than their corresponding carcinomas, consistent with
multi-hit model of cancer progression, and particularly
applicable for tumors of epithelial origin, where more
advanced cancers have more mutations in their DNA. The
maximum multiplicity values are reversed for genes, with
early causal genes having higher multiplicity values, indi-
cating that early causal genes are systemic across cancers.
Gene cluster 4, which has the highest multiplicity value
and containing 23 of the 24 genes associated with precan-
cerous tumors gives evidence that the clustering technique
separates early initiating genes. Work has been done on
mutually exclusive and co-occurring gene pattern in path-
ways from COSMIC [31], and a next step would be to
integrate findings of gene co-occurrence and exclusivity
with multiplicity clustering. The bias in the COSMIC data
set makes comparing multiplicity clusters and co-occur-
ring genes difficult, but it will be possible with whole gen-
ome analysis to assess co-occurrence and multiplicity
together. Although the order of gene mutations is stochas-
tic, multiplicity can be used to separate the general pro-
gression of these mutations, given sufficient granularity of
tumor tissue and genomic measurements.
These multiplicity measures offer a cost-effective way
to discover new knowledge using data from previous
studies. Additional benefits of the measures will be
achieved when sufficient detailed genomic information
is available to classify tumors of patients recently diag-
nosed with a particular cancer. Potentially, distributions
of multiplicity measures could be used to characterize
severity and type of tumor for individual patients.
Clinical relevance
In clinical settings, tumors are largely classified accord-
ing to anatomic location, histological type, subtype, and
stage [32]. Histological features, which until now have
dominated the subtyping of tumors, do not provide a
complete reflection of the molecular alterations that can
drive tumor growth and aggressiveness. For example,
colonic tumors that penetrate the muscularis, with or
without lymph node involvement, have overlapping out-
comes. Thus, while microscopic inspection of colonic
tumors may be adequate for differentiating benign
polyps from malignant growths, it may be inadequate
for predicting the aggressive behavior of malignant
tumors.
Because the usefulness of localization and appearance
for classifying cancers and determining optimal thera-
pies is limited [33], alternative approaches are war-
ranted. Somatic mutations play an important role in
cancer initiation and progression, as well as in prognosis
[9]. However, biomedical research about somatic muta-
tions has generally been limited to a few genes in a few
cancer types. Our informatics methods can augment
research into the molecular basis of disease, using data
from decades of studies to identify similarities in
somatic mutation patterns that characterize similar can-
cer types. In cases where histological examination pro-
duces uncertain diagnoses, individual tumors could
conceivably be examined for mutation patterns and
compared to a space of tumors constructed from the
multiplicity of their somatic mutation patterns. Similar
to the situation with overexpression of a molecular tar-
get, somatic mutations that have been profiled exten-
sively for some cancer types may provide useful
guidance for research into other poorly understood can-
cer types that have similar somatic mutation patterns.
A tool that identifies patterns in somatic mutations
shared across multiple cancer types can be useful to iden-
tify a broad selection of cancers that might benefit from
molecular diagnostics of one or more somatic mutations
coupled with targeted therapy. For example, breast cancers
are routinely tested using immunohistochemistry to detect
overexpression of the Her-2/neu oncogene; cancers with
this overexpression are treated with the targeted therapy
trastuzumab. However, tumors with a PI3 kinase
(PIK3CA) mutation that results in constitutive kinase
activity will be resistant to trastuzumab [34]. A number of
other inhibitors have been developed that target PI3K
activity; some are now being tested in early clinical trials
in non-small-cell lung, breast, ovarian, endometrial, brain,
and multiple leukemia and lymphoma cancers [35].
Multiplicity analysis of somatic mutations could iden-
tify those with the highest multiplicity as those most
likely to be effective molecular targets across multiple
tumor types. In addition, one can study the impact of
associated mutations on the efficacy of novel targeted
therapies across multiple tumor types that share
mutations.
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(TCGA) [36], more detailed information on alterations
of the cancer genome is becoming available. The analy-
sis described here can be generalized to other alterations
by substituting the multiplicity of somatic mutations
with that of copy number, methylation, or microarray
data. The data will need to cover many different types
of cancer in order to assess the multiplicity of the
alterations across cancers.
With a principled organization of whole tumor gen-
omes, both prognostic and predictive testing based on
genomic data could become common practice. Identifi-
cation of somatic mutations, either alone or in combina-
tion, could be useful to physicians as a supplement to
the histological and immunohistochemical findings cur-
rently used to establish diagnosis and prognosis. A mul-
tiplicity-based clustering methodology can be a tool to
organize the genomic data and to identify somatic muta-
tions occurring in similar sets of cancer.
Limitation
As the creators of COSMIC have suggested [13], this
data set is likely to contain an ethnic bias in which a
disproportionate number of samples originated from the
United States and Europe. COSMIC also has a prior
knowledge bias due to the collection of mutation data
focusing on many core cancer genes. The clustering
technique generates stable clusters from the three-
dimensional multiplicity space and increases in stability
as sample across subtypes increases. The number of
samples available for each subtype limits the granularity
of the disease classification. Therefore, somatic muta-
tions that may be relevant to a particular subtype of a
disease will be associated with the larger disease group.
This limitation can be addressed in future work as more
data become available across subtypes of diseases. These
limitations of the data set do not affect the organizing
principle of multiplicity and will be resolved as the mea-
sure is applied to whole genome data on tumors.
Despite these limitations, COSMIC appears to be a valu-
able resource for developing knowledge representations
with potential bench research and clinical relevance.
Conclusion
Our results demonstrate the power of a method based
on the principle of multiplicity to cluster genetic muta-
tions and relate them to the cancer types in which they
occur. The concept of multiplicity builds upon Fearon
and Vogelstein’s multi-hit genetic model of colorectal
cancer and generalizes across cancer types. As an orga-
nization tool, this approach is helpful in identifying
somatic mutations as candidates for targeted therapy
that are most likely to impact multiple cancer types, and
it identifies associations of mutations that may be
informative as to mechanisms of resistance to targeted
therapy.
An interesting result of our analysis is that it is more
than a solution to the problem of organizing complex
genomic data for human interpretation. The results
show that genetic mutations known to be causal corre-
late with high multiplicity. This way of organizing the
data lends support to the hypothesis that other genetic
mutations with high multiplicity might also have a cau-
sal role in the stepwise progression of normal cells to
the neoplastic and frankly malignant states. The organi-
zation of the data also allows the user to generate
hypotheses concerning the role of the tissue type, local
anatomic site, or even particular cancer type in promot-
ing genetic mutations that lack high multiplicity.
The concept can be generalized beyond somatic muta-
tions to other modalities such copy number, methyla-
tion, and microarray data. The application of the
method to these modalities will depend on having suffi-
cient sample across a collection of cancer types. The
method’s effectiveness at generating meaningful repre-
sentations from COSMIC forecasts what can be discov-
ered with whole genome analysis of tumor samples. A
well-characterized genomic space of genes and cancer
types constructed with the principle of multiplicity
could be used to compare and cluster patients’ tumor
samples, potentially resulting in improved diagnostic
and prognostic capabilities in clinical practice. It will
also be interesting to see how sequence data and expres-
sion data correlate. It is not clear that somatic muta-
tions will have a uniform effect on gene expression for
the mutated gene, although a somatic mutation in a
c a u s a t i v eg e n em a yr e s u l ti nau n i q u eg e n ee x p r e s s i o n
signature. Given the recent investment of the National
Cancer Institute in creating TCGA, which contains
genomic information from multiple platforms across
multiple tumor types, we feel that multiplicity analysis
can be utilized to organize the information and engen-
der hypotheses about functional causality from discov-
ered associations.
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Additional file 1: Hierarchical clustering for causal germline
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these 34 causal germline mutations is made available through Additional
file 1.
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As a supplemental resource, a CSV file is included that provides a gene
maximum multiplicity value for each gene.
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